

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 October 2005 (27.10.2005)

PCT

(10) International Publication Number
WO 2005/099740 A1

(51) International Patent Classification⁷: **A61K 38/05**,
A61P 25/06, A61K 31/16, 31/165

(21) International Application Number:
PCT/EP2005/004047

(22) International Filing Date: 15 April 2005 (15.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/562,681 16 April 2004 (16.04.2004) US

(71) Applicant (for all designated States except US):
SCHWARZ PHARMA AG [DE/DE]; Alfred-No-
bel-Straße 10, 40789 Monheim (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SCHELLER, Di-
eter** [DE/DE]; Bettikumer Dorfstr. 13, 41470 Neuss (DE).
STÖHR, Thomas [DE/DE]; Marie-Curie-Str. 24, 40789
Monheim (DE).

(74) Agents: **WEICKMANN & WEICKMANN** et al.; Post-
fach 860 820, 81635 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF PEPTIDIC COMPOUNDS FOR THE PROPHYLAXIS AND TREATMENT OF CHRONIC HEADACHE

(57) Abstract: The present invention is directed to the use of a class of peptide compounds for the prophylaxis and treatment of chronic headache, particularly migraines.



WO 2005/099740 A1

Use of Peptidic Compounds for the Prophylaxis and Treatment of Chronic Headache


Description

The present invention is directed to the use of a class of peptidic compounds for the prophylaxis and treatment of chronic headache, particularly migraine.

5

Certain peptides are known to exhibit central nervous system (CNS) activity and are useful in the treatment of epilepsy and other CNS disorders. These peptides which are described in the U.S. Patent No. 5,378,729 have the Formula (Ia):

10



15

Formula (Ia)

20

wherein

R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl lower alkyl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, and R is unsubstituted or is substituted with at least one electron withdrawing group or electron donating group;

R₁ is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic lower alkyl, heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, each unsubstituted or substituted with an electron donating group or an electron withdrawing group; and

30


- 2 -

R_2 and R_3 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, or Z-Y
 5 wherein R_2 and R_3 may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group;

Z is O, S, $S(O)_a$, NR_4 , PR_4 or a chemical bond;

10 Y is hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic lower alkyl, and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo, Z is a chemical bond, or

15 ZY taken together is $NR_4NR_5R_7$, NR_4OR_5 , ONR_4R_7 , OPR_4R_5 , PR_4OR_5 , SNR_4R_7 , NR_4SR_7 , SPR_4R_5 or PR_4SR_7 , $NR_4PR_5R_6$ or $PR_4NR_5R_7$,



R_4 , R_5 and R_6 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, or lower alkynyl, wherein R_4 , R_5 and R_6 may be unsubstituted or substituted with an electron withdrawing group or an electron donating
 25 group; and

R_7 is R_6 or $COOR_8$ or COR_8 ;

R_8 is hydrogen or lower alkyl, or aryl lower alkyl, and the aryl or alkyl group
 30 may be unsubstituted or substituted with an electron withdrawing group or an electron donating group; and


n is 1-4; and

a is 1-3.

U.S. Patent No. 5,773,475 also discloses additional compounds useful for treating CNS disorders. These compounds are N-benzyl-2-amino-3-methoxy-propionamide having the Formula (IIa):

5

10



Formula (IIa)

15 wherein

Ar is aryl which is unsubstituted or substituted with halo; R_3 is lower alkoxy; and R_1 is methyl.

20 The patents US 5.378.729 and US 5.773.475 are hereby incorporated by reference. However, neither of these patents describes the use of these compounds as specific analgesics for the treatment of chronic headache.

WO 02/074297 relates to the use of a compound according to Formula (IIa) wherein Ar is phenyl which may be substituted by at least one halo, R_3 is lower alkoxy containing 1-3 carbon atoms and R_1 is methyl for the preparation of pharmaceutical compositions useful for the treatment of allodynia related to peripheral neuropathic pain.

WO 02/074784 relates to the use of a compound having Formula (Ia) or/and Formula (IIa) showing antinociceptive properties for treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain, e.g. rheumatoid arthritic pain or/and secondary inflammatory osteo-arthritic pain.

A person suffering from headache can experience pain in several areas of the head, including a network of nerves that extends over the scalp and certain nerves in the face, mouth, and throat. The muscles of the head and the blood vessels found along the surface and at the base of the brain are also sensitive to pain because they contain delicate nerve fibers. The bones of the skull and tissues of the brain itself do not hurt because they lack pain-sensitive nerve fibers. The ends of these pain-sensitive nerves, called nociceptors, can be stimulated by stress, muscular tension, dilated blood vessels, and other headache triggers. Vascular headaches (such as migraines, for instance) are thought to involve abnormal function of the brain's blood vessels or vascular system; muscle contraction headaches appear to involve the tightening or tensing of facial and neck muscles; while traction and inflammatory headaches are symptoms of other disorders, ranging from brain tumor to stroke or sinus infection. Some types of headache are signals of more serious disorders: sudden, severe headache; headache associated with convulsions; headache accompanied by confusion or loss of consciousness; headache following a blow on the head; headache associated with pain in the eye or ear; persistent headache in a person who was previously headache free; recurring headache in children; headache associated with fever; headache that interferes with normal life.

Headaches are diagnosed as vascular, muscle contraction (tension), traction or inflammatory headaches.

The most common type of vascular headache is migraine. Migraine is the most common neurological condition in the developed world. It affects about 10% of the population and is more prevalent than diabetes, epilepsy and asthma combined. Migraine is more than just a headache. It can be a debilitating condition which has a considerable impact on the quality of life of sufferers and their families. Attacks can be completely disabling, forcing the sufferer to abandon everyday activities for up to 3 days. Even in symptom-free periods, sufferers may live in fear of the next attack. The pain of a migraine headache is often described as an intense pulsing or throbbing

pain in one area of the head. It is often accompanied by extreme sensitivity to light and sound, nausea, and vomiting. Migraine is three times more common in women than in men. Some individuals can predict the onset of a migraine because it is preceded by an "aura," visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a lack of food or sleep, exposure to light, or hormonal irregularities (only in women). Anxiety, stress or relaxation after stress can also be triggers. For many years, scientists believed that migraines were linked to the dilation and constriction of blood vessels in the head. Investigators now believe that migraine is caused by inherited abnormalities in genes that control the activities of certain cell populations in the brain. There are two ways to approach the treatment of migraine headache with drugs: prevention of the attacks or the relief of the symptoms during the attacks. Many people with migraine use both approaches by taking medications originally developed for epilepsy and depression to prevent future attacks, and treating attacks when they happen with drugs called triptans that relieve pain and restore function.

After migraine, the most common type of vascular headache is the toxic headache produced by fever. Pneumonia, measles, mumps, and tonsillitis are among the diseases that can cause severe toxic vascular headaches. Toxic headaches can also result from the presence of foreign chemicals in the body.

Other kinds of vascular headaches include "clusters," which cause repeated episodes of intense pain, and headaches resulting from a rise in blood pressure. Cluster headaches, named for their repeated occurrence in clusters over weeks or months at roughly the same time of day or night, begin as a minor pain around one eye, eventually spreading to that side of the face. The pain quickly intensifies, compelling the victim to pace the floor or rock in a chair, for instance. Other symptoms include a stuffed and runny nose and a droopy eyelid over a red and weeping eye. Cluster headaches last between 30 and 45 minutes but the relief people feel at the end of an

attack is usually mixed with dread as they await a recurrence. Clusters may mysteriously disappear for months or years. Many people have cluster bouts during the spring and fall. At their worst, chronic cluster headaches can last continuously for years. Cluster attacks can strike at any age but usually start
5 between the ages of 20 and 40. Unlike migraine, cluster headaches are more common in men and do not run in families. Paradoxically, both nicotine, which constricts arteries, and alcohol, which dilates them, trigger cluster headaches. The exact connection between these substances and cluster attacks is not known. The sudden start and brief duration of cluster
10 headaches can make them difficult to treat but research scientists have identified several effective drugs for these headaches. The antimigraine drug sumatriptan can subdue a cluster if taken at the first sign of an attack. Injections of dihydroergotamine, a form of ergotamine tartrate, are sometimes used to treat clusters. Corticosteroids also can be used, either
15 orally or by intramuscular injection. For instance, attacks can be prevented by taking anti-epileptic drugs such as valproic acid.

Muscle contraction (tension) type headache is named not only for the role played by stress in triggering the pain, but also for the contraction of neck,
20 face, and scalp muscles brought on by stressful events. Tension headache is a severe but temporary form of muscle-contraction headache. The pain is mild to moderate and feels like pressure is being applied to the head or neck. The headache usually disappears after the period of stress is over. Ninety percent of all headaches are classified as tension/muscle contraction
25 headaches. In contrast, chronic muscle-contraction headaches can last for weeks, months and sometimes years. The pain associated with these headaches is often described as a tight band around the head or a feeling that the head and neck are in a cast. The pain is steady and is usually felt on both sides of the head. Chronic muscle-contraction headaches can cause a
30 sore scalp - even combing one's hair can be painful. In the past, many scientists believed that the primary cause of the pain of muscle-contraction headache was sustained muscle tension. However, a growing number of experts now believe that a far more complex mechanism is responsible.

Occasionally, muscle-contraction headaches will be accompanied by nausea, vomiting, and blurred vision but there is no pre-headache syndrome as with migraine. Muscle-contraction headaches have not been linked to hormones or foods, as has migraine, nor is there a strong hereditary connection. Research has shown that for many people, chronic muscle-contraction headaches are caused by depression and anxiety. These people tend to get their headaches in the early morning or evening when conflicts in the office or home are anticipated. Emotional factors are not the only triggers of muscle-contraction headaches. Certain physical postures that tense head and neck muscles can lead to head and neck pain, such as holding one's chin down while reading, prolonged writing under poor light, holding a phone between the shoulder and ear, or even gum-chewing. Acute tension headaches not associated with a disease are treated with analgesics such as aspirin and acetaminophen. Stronger analgesics, such as propoxyphene and codeine, are sometimes prescribed. Prolonged use of these drugs can lead to dependence, however. People with chronic muscle-contraction headaches may also be helped by taking antidepressants or MAO inhibitors. Mixed muscle-contraction and migraine headaches are sometimes treated with anti-epileptic drugs or barbiturate compounds, which slow down nerve function in the brain and spinal cord.

Like other types of pain, headaches can serve as warning signals for more serious disorders. This is particularly true for headaches caused by traction or inflammation. Traction headaches can occur if the pain-sensitive parts of the head are pulled, stretched, or displaced, as when eye muscles are tensed to compensate for eyestrain, for example. Headaches caused by inflammation include those related to meningitis as well as those resulting from diseases of the sinuses, spine, neck, ears and teeth. Ear and tooth infections as well as glaucoma can cause headaches. In oral and dental disorders, headache is experienced as pain in the entire head, including the face. These headaches are treated by curing the underlying problem. This may involve surgery, antibiotics or other drugs. Characteristics of the various types of more serious traction and inflammatory headaches vary

depending on the disorder, these being brain tumors, stroke, spinal taps, trigeminal neuralgia, head trauma, arteritis or meningitis, for example.

Cortical spreading depression (CSD), already described by Leao in 1944 (Leao AAP (1944) *Spreading depression of activity in the cerebral cortex*. J Neurophysiol 7:359-390), is a transient suppression of cortical activity which starts locally and spreads through the tissue with a speed of approximately 3 mm/min. It is associated with the dilatation of pial arterioles, resulting in a cerebral blood flow (CBF) hyperperfusion and followed by a long-lasting hypoperfusion of several hours. The underlying mechanisms and physiological role of these blood flow related changes observed in CSD are still not fully understood. Several vasoactive parenchymal metabolites, such as K^+ , CO_2 , adenosine, NO and glutamate, are known to be released during CSD and may contribute to pial vasodilatation. Furthermore, neurotransmitters released from perivascular nerve fibers surrounding cortical pial vessels may also participate in CSD-associated vasodilatation. These neurotransmitters belong mainly to the trigeminal, sympathetic, and parasympathetic nervous systems. Calcitonin gene-related peptide (CGRP), substance P and neurokinin A have been demonstrated immunohistochemically as transmitters of perivascular trigeminal nerves originating in the ipsilateral division of the trigeminal ganglia cells and continue in the nasociliary nerve. The trigeminovascular system is the anatomic substrate for the key hypothesis of migraine pathophysiology. Trigeminal neurotransmitters (like CGRP) contribute substantially to vasodilation in several physiological and pathophysiological conditions. In CSD the brain stem nucleus caudalis becomes activated, as demonstrated by the induction of c-fos, which is blocked by meningeal deafferentation. CSD leads to trigeminal activation and putatively to the release of neurotransmitters from this system.

There is strong evidence that CSD serves as the initiating event for migraine visual aura and pain. Bolay et al. (Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA, 2002, *Intrinsic brain activity triggers trigeminal*

meningeal afferents in a migraine, Nat. Med. 8:136-42) established a link between migraine aura and headache by demonstrating that CSD activates trigeminovascular afferents and evokes a series of cortical meningeal and brainstem events consistent with the development of headache. CSD
5 caused long-lasting blood-flow enhancement selectively within the middle meningeal artery dependent upon trigeminal and parasympathetic activation, and plasma protein leakage within the dura mater in part by a neurokinin-1-receptor mechanism. The findings provide a neural mechanism by which extracerebral cephalic blood flow couples to brain events; this
10 mechanism explains vasodilation during headache and links intense neurometabolic brain activity with the transmission of headache pain by the trigeminal nerve.

A number of evidences suggest involvement of CSD in cerebrovascular
15 diseases. Damage to cerebral tissue during ischemia depends on a complex series of physiological responses and degradative cellular cascades involving a dynamic interplay among the various cells in the region of damaged tissue. Experimental studies support the concept that there is a core of severe ischemia and a focal ischemic insult and that the ischemic
20 core is surrounded by a region of reduced perfusion, the ischemic penumbra. Within the ischemic core, failure of oxygen and glucose delivery leads to rapid depletion of energy stores and cell death. Central to the hypothesis of neuronal salvage is the concept of the ischemic penumbra. The penumbra is an area where metabolic capacity is suppressed but
25 destruction is not yet inevitable. The etiology of progressive cell injury and death in the penumbra zone has been clarified to some extent. Evidence suggests that CSD plays a role in the ischemia-infarction tissue damage process. A profound increase in extracellular potassium occurs in the ischemic core. There is a suggestion that the high potassium concentration
30 in the ischemic focus initiates diffusion of potassium ions into the adjacent normally perfused cortex and triggers CSD waves propagating from the rim of the focus to the surrounding intact tissue during the early stages of focal ischemia. These CSD waves cause an additional metabolic burden to the so

far intact tissue and thus contribute to the growth of the ischemic core. Generation of CSD has been observed during an approximately 2h period after ischemia, followed by a shorter interval of increased CSD susceptibility which disappears 3-4h after the onset of ischemia. Such CSD waves, which
5 are significantly longer than those observed in the intact cortex, can be potentially harmful because they are accompanied by additional release of glutamate and influx of calcium into the neurons. In energy deprived neurons such as seen in the ischemic penumbra this is enough to initiate a cell death cascade. Preventing the occurrence of CSD in the post-ischemic
10 period might therefore reduce ischemic brain damage.

Other clinical indications associated with CSD include intracranial hemorrhage and head injury. Some biochemical changes in the composition of the microenvironment during brain injury, such as high lactate and
15 glucose concentrations in the cerebrospinal fluid, are also observed during CSD. Moreover, in single cases CSD could be observed in the living human cortex of patients with severe head injury. Following intracranial hemorrhage, delayed ischemic deficits are observed. It is believed that CSDs are critically involved in these delayed ischemic deficits (Gorji A.
20 *Spreading depression: a review of the clinical relevance*. Brain Res. Rev. 38, 2001; 33-60). Consequently, a blockade of CSD might prevent the long-term consequences of intracranial hemorrhage and head injury.

Another clinical syndrome associated with CSD is transient global amnesia.
25 Transient global amnesia is characterised by a sudden onset of complete memory loss and learning ability, usually occurring in late middle age. Such amnesic attacks occur, for instance, during migraine aura, during which CSDs have been observed. In animal experiments, the induction of either cortical or subcortical CSD can cause amnesia and learning impairments.
30 This demonstrates that a blockade of CSD might be beneficial for transient global amnesia.


The use of compounds of Formula (Ib) or/and Formula (IIb) for the

suppression of cortical spreading depression (CSD) has not been reported. Thus, the present invention concerns the use of compounds of Formulae (Ib) or/and (IIb) for the preparation of a pharmaceutical composition for the prevention, alleviation or/and treatment of headache, especially chronic headache such as migraine. Further, the present invention concerns the use
5 of compounds of Formulae (Ib) or/and (IIb) for the preparation of a pharmaceutical composition for the prevention, alleviation or/and treatment of all types of painful conditions associated with or/and caused by CSD, such as, but not limited to, cerebral ischemia during stroke or cardiovascular
10 surgery, for instance, traumatic brain injury, subarachnoid hemorrhage or transient global amnesia. Preferred, but not limited to, is the use of compounds of Formulae (Ib) or/and (IIb) for the preparation of a pharmaceutical composition for the prevention, alleviation or/and treatment of chronic headache associated with or/and caused by CSD such as
15 migraine or other forms of chronic headache of both central and peripheral origin such as, but not limited to, cluster headache, tension-type headache or secondary headaches associated with over use of medication, cranial neuralgias, brain trauma and vascular or metabolic disorders, for example. Especially preferred is the treatment of acute migraine.

20 Surprisingly, application of compounds (Ib) or/and (IIb), particularly (R)-2-acetamide-N-benzyl-3-methoxypropionamide (SPM 927) exhibited a significant suppression of CSD and a CSD-induced release of calcitonin gene-related peptide (CGRP) in an animal model for migraine.

25 The invention is applicable in animals, particularly mammals, including humans.

A compound according to the invention useful for the prevention, alleviation
30 or/and treatment of headache or/and conditions associated or/and caused by CSD, particularly chronic headache such as migraine has the general Formula (Ib)

**Formula (Ib)**

wherein

R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl lower alkyl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl or lower cycloalkyl lower alkyl, and R is unsubstituted or is substituted with at least one electron withdrawing group, or/and at least one electron donating group;

R₁ is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic lower alkyl, lower alkyl heterocyclic, heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, each unsubstituted or substituted with at least one electron donating group or/and at least one electron withdrawing group;

and

R₂ and R₃ are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, halo, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, or Z-Y wherein R₂ and R₃ may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group;

- 13 -

Z is O, S, S(O)_a, NR₄, NR'₆, PR₄ or a chemical bond;

Y is hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic and Y
 5 may be unsubstituted or substituted with at least one electron donating group or/and at least one electron withdrawing group, provided that when Y is halo, Z is a chemical bond, or

ZY taken together is NR₄NR₅R₇, NR₄OR₅, ONR₄R₇, OPR₄R₅, PR₄OR₅,
 10 SNR₄R₇, NR₄SR₇, SPR₄R₅, PR₄SR₇, NR₄PR₅R₆, PR₄NR₅R₇ or N⁺R₅R₆R₇,

$$\begin{array}{ccccc} \text{NR}_4\text{C}-\text{R}_5, & \text{SCR}_5, & \text{NR}_4\text{C}-\text{OR}_5, & \text{SC}-\text{OR}_5, & \text{NR}_4\text{NR}_5-\text{C}-\text{OR}_6; \\ \parallel & \parallel & \parallel & \parallel & \parallel \\ \text{O} & \text{O} & \text{O} & \text{O} & \text{O} \end{array}$$

15 R'₆ is hydrogen, lower alkyl, lower alkenyl, or lower alkynyl which may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group;

R₄, R₅ and R₆ are independently hydrogen, lower alkyl, aryl, aryl lower alkyl,
 20 lower alkenyl, or lower alkynyl, wherein R₄, R₅ and R₆ may independently be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group;


R₇ is R₆ or COOR₈ or COR₈, which R₇ may be unsubstituted or substituted
 25 with at least one electron withdrawing group or/and at least one electron donating group;

R₈ is hydrogen or lower alkyl, or aryl lower alkyl, and the aryl or alkyl group
 30 may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group; and

n is 1-4; and

a is 1-3.

Preferably the compound has the general Formula (IIb)



Formula (IIb)

wherein

15 Ar is aryl, especially phenyl, which is unsubstituted or substituted with at least one halo; R₃ is -CH₂-Q, wherein Q is lower alkoxy; and R₁ is lower alkyl, especially methyl.

20 The present invention is also directed to a pharmaceutical composition comprising a compound according to Formula (Ib) or/and Formula (IIb) useful for the prevention, alleviation or/and treatment of headache, especially for the prevention, alleviation or/and treatment of headache, or/and a disorder associated with or/and caused by CSD such as migraine.

25 The compounds of Formula (Ia) are described in U.S. Patent No. 5,378,729, the contents of which are incorporated by reference.

30 The "lower alkyl" groups when used alone or in combination with other groups, are lower alkyl containing from 1 to 6 carbon atoms, especially 1 to 3 carbon atoms, and may be straight chain or branched. These groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, amyl, hexyl, and the like.

35 The "lower alkoxy" groups are lower alkoxy containing from 1 to 6 carbon atoms, especially 1 to 3 carbon atoms, and may be straight chain or branched. These groups include methoxy, ethoxy, propoxy, butoxy,

isobutoxy, tert-butoxy, pentoxy, hexoxy and the like.

The "aryl lower alkyl" groups include, for example, benzyl, phenethyl, phenylpropyl, phenylisopropyl, phenylbutyl, diphenylmethyl, 1,1-
5 diphenylethyl, 1,2-diphenylethyl, and the like.

The term "aryl", when used alone or in combination, refers to an aromatic group which contains from 6 up to 18 ring carbon atoms and up to a total of 25 carbon atoms and includes the polynuclear aromatics. These aryl groups
10 may be monocyclic, bicyclic, tricyclic or polycyclic and are fused rings. A polynuclear aromatic compound as used herein, is meant to encompass bicyclic and tricyclic fused aromatic ring systems containing from 10-18 ring carbon atoms and up to a total of 25 carbon atoms. The aryl group includes phenyl, and the polynuclear aromatics e.g., naphthyl, anthracenyl,
15 phenanthrenyl, azulenyl and the like. The aryl group also includes groups like ferrocenyl. Aryl groups may be unsubstituted or mono or polysubstituted with electron withdrawing or/and electron donating groups as described below.

20 "Lower alkenyl" is an alkenyl group containing from 2 to 6 carbon atoms and at least one double bond. These groups may be straight chained or branched and may be in the Z or E form. Such groups include vinyl, propenyl, 1-butenyl, isobutenyl, 2-butenyl, 1-pentenyl, (Z)-2-pentenyl, (E)-2-pentenyl, (Z)-4-methyl-2-pentenyl, (E)-4-methyl-2-pentenyl, pentadienyl,
25 e.g., 1, 3 or 2,4-pentadienyl, and the like.

The term "lower alkynyl" is an alkynyl group containing 2 to 6 carbon atoms and may be straight chained as well as branched. It includes such groups as ethynyl, propynyl, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 3-methyl-1-
30 pentyne, 3-pentyne, 1-hexyne, 2-hexyne, 3-hexyne and the like.

The term "lower cycloalkyl" when used alone or in combination is a cycloalkyl group containing from 3 to 18 ring carbon atoms and up to a total

of 25 carbon atoms. The cycloalkyl groups may be monocyclic, bicyclic, tricyclic, or polycyclic and the rings are fused. The cycloalkyl may be completely saturated or partially saturated. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclohexenyl, cyclopentenyl, cyclooctenyl, cycloheptenyl, decaliny, hydroindanyl, indanyl, fenchyl, pinenyl, adamantyl, and the like. Cycloalkyl includes the cis or trans forms. Cycloalkyl groups may be unsubstituted or mono or polysubstituted with electron withdrawing or/and electron donating groups as described below. Furthermore, the substituents may either be in endo or exo positions in the bridged bicyclic systems.

The term "electron-withdrawing and electron donating" refer to the ability of a substituent to withdraw or donate electrons, respectively, relative to that of hydrogen if the hydrogen atom occupied the same position in the molecule. These terms are well understood by one skilled in the art and are discussed in Advanced Organic Chemistry, by J. March, John Wiley and Sons, New York, NY, pp.16-18 (1985) and the discussion therein is incorporated herein by reference. Electron withdrawing groups include halo, including bromo, fluoro, chloro, iodo and the like; nitro, carboxy, lower alkenyl, lower alkynyl, formyl, carboxyamido, aryl, quaternary ammonium, halo alkyl such as trifluoromethyl, aryl lower alkanoyl, carbalkoxy and the like. Electron donating groups include such groups as hydroxy, lower alkoxy, including methoxy, ethoxy and the like; lower alkyl, such as methyl, ethyl, and the like; amino, lower alkylamino, di(loweralkyl) amino, aryloxy such as phenoxy, mercapto, lower alkylthio, lower alkylmercapto, disulfide (lower alkyldithio) and the like. One of ordinary skill in the art will appreciate that some of the aforesaid substituents may be considered to be electron donating or electron withdrawing under different chemical conditions. Moreover, the present invention contemplates any combination of substituents selected from the above-identified groups.

The term "halo" includes fluoro, chloro, bromo, iodo and the like.

The term "acyl" includes lower alkanoyl containing from 1 to 6 carbon atoms and may be straight chains or branched. These groups include, for example, formyl, acetyl, propionyl, butyryl, isobutyryl, tertiary butyryl, pentanoyl and hexanoyl.

5

As employed herein, a heterocyclic group contains at least one sulfur, nitrogen or oxygen ring atom, but also may include several of said atoms in the ring. The heterocyclic groups contemplated by the present invention include heteroaromatics and saturated and partially saturated heterocyclic compounds. These heterocyclics may be monocyclic, bicyclic, tricyclic or polycyclic and are fused rings. They may preferably contain up to 18 ring atoms and up to a total of 17 ring carbon atoms and a total of up to 25 carbon atoms. The heterocyclics are also intended to include the so-called benzoheterocyclics. Representative heterocyclics include furyl, thienyl, pyrazolyl, pyrrolyl, methylpyrrolyl, imidazolyl, indolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, piperidyl, pyrrolinyl, piperazinyl, quinolyl, triazolyl, tetrazolyl, isoquinolyl, benzofuryl, benzothienyl, morpholinyl, benzoxazolyl, tetrahydrofuryl, pyranyl, indazolyl, purinyl, indolyl, pyrazolindinyl, imidazolindyl, imadazolindinyl, pyrrolidinyl, furazanyl, N-methylindolyl, methylfuryl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridyl, epoxy, aziridino, oxetanyl, azetidyl, the N-oxides of the nitrogen containing heterocycles, such as the N-oxides of pyridyl, pyrazinyl, and pyrimidinyl and the like. Heterocyclic groups may be unsubstituted or mono or poly substituted with electron withdrawing or/and electron donating groups.

25

The preferred heterocyclics are thienyl, furyl, pyrrolyl, benzofuryl, benzothienyl, indolyl, methylpyrrolyl, morpholinyl, pyridyl, pyrazinyl, imidazolyl, pyrimidinyl, or pyridazinyl. The preferred heterocyclic is a 5 or 6-membered heterocyclic compound. The especially preferred heterocyclic is furyl, pyridyl, pyrazinyl, imidazolyl, pyrimidinyl, or pyridazinyl. The most preferred heterocyclics are furyl and pyridyl.

30

The preferred compounds are those wherein n is 1, but di (n=2), tri (n=3)

and tetrapeptides (n=4) are also contemplated to be within the scope of the invention.

5 The preferred values of R is aryl lower alkyl, especially benzyl especially those wherein the phenyl ring thereof is unsubstituted or substituted with electron donating groups or/and electron withdrawing groups, such as halo (e.g., F).

10 The preferred R₁ is H or lower alkyl. The most preferred R₁ group is methyl.

The preferred electron donating substituents or/and electron withdrawing substituents are halo, nitro, alkanoyl, formyl, arylalkanoyl, aryloyl, carboxyl, carbalkoxy, carboxamido, cyano, sulfonyl, sulfoxide, heterocyclic, guanidine, quaternary ammonium, lower alkenyl, lower alkynyl, sulfonium salts, 15 hydroxy, lower alkoxy, lower alkyl, amino, lower alkylamino, di(loweralkyl) amino, amino lower alkyl, mercapto, mercaptoalkyl, alkylthio, and alkylidithio. The term "sulfide" encompasses mercapto, mercapto alkyl and alkylthio, while the term disulfide encompasses alkylidithio. Especially preferred electron donating or/and electron withdrawing groups are halo or lower 20 alkoxy, most preferred are fluoro or methoxy. These preferred substituents may be substituted on any one of R, R₁, R₂, R₃, R₄, R₅, R₆, R'₆, R₇, R₈ or/and R₅₀ as defined herein.

25 The ZY groups representative of R₂ and R₃ include hydroxy, alkoxy, such as methoxy, ethoxy, aryloxy, such as phenoxy; thioalkoxy, such as thiomethoxy, thioethoxy; thioaryloxy such as thiophenoxy; amino; alkylamino, such as methylamino, ethylamino; arylamino, such as anilino; lower dialkylamino, such as, dimethylamino; trialkyl ammonium salt, hydrazino; alkylhydrazino and arylhydrazino, such as N-methylhydrazino, N- 30 phenylhydrazino, carbalkoxy hydrazino, aralkoxycarbonyl hydrazino, aryloxycarbonyl hydrazino, hydroxylamino, such as N-hydroxylamino (-NH-OH), lower alkoxy amino [(NHOR₁₈) wherein R₁₈ is lower alkyl], N-lower alkylhydroxyl amino [(NR₁₈)OH wherein R₁₈ is lower alkyl], N-lower alkyl-O-


- 19 -

lower alkylhydroxyamino, i.e., $[N(R_{18})OR_{19}]$ wherein R_{18} and R_{19} are independently lower alkyl], and o-hydroxylamino ($-O-NH_2$); alkylamido such as acetamido; trifluoroacetamido; lower alkoxyamino, (e.g., $NH(OCH_3)$); and heterocyclicamino, such as pyrazoylamino.

5

The preferred heterocyclic groups representative of R_2 and R_3 are monocyclic 5- or 6-membered heterocyclic moieties of the formula:

10



15

or those corresponding partially or fully saturated form thereof wherein n is 0 or 1; and

20

R_{50} is H or an electron withdrawing group or electron donating group;

A, E, L, J and G are independently CH, or a heteroatom selected from the group consisting of N, O, S;

25

but when n is 0, G is CH, or a heteroatom selected from the group consisting of NH, O and S with the proviso that at most two of A, E, L, J and G are heteroatoms.

30

When n is 0, the above heteroaromatic moiety is a five membered ring, while if n is 1, the heterocyclic moiety is a six membered monocyclic heterocyclic moiety. The preferred heterocyclic moieties are those aforementioned heterocyclics which are monocyclic.

If the ring depicted hereinabove contains a nitrogen ring atom, then the N-

oxide forms are also contemplated to be within the scope of the invention.

When R_2 or R_3 is a heterocyclic of the above formula, it may be bonded to the main chain by a ring carbon atom. When n is 0, R_2 or R_3 may additionally
 5 be bonded to the main chain by a nitrogen ring atom.

Other preferred moieties of R_2 and R_3 are hydrogen, aryl, e.g., phenyl, aryl alkyl, e.g., benzyl and alkyl.


10 It is to be understood that the preferred groups of R_2 and R_3 may be unsubstituted or mono or poly substituted with electron donating or/and electron withdrawing groups. It is preferred that R_2 and R_3 are independently hydrogen, lower alkyl, which is either unsubstituted or substituted with
 15 electron withdrawing groups or/and electron donating groups, such as lower alkoxy (e.g., methoxy, ethoxy, and the like), N-hydroxylamino, N-lower alkylhydroxyamino, N-loweralkyl-O-loweralkyl and alkylhydroxyamino.

It is preferred that one of R_2 and R_3 is hydrogen.

20 It is preferred that n is one.

It is more preferred that $n=1$ and one of R_2 and R_3 is hydrogen. It is especially preferred that in this embodiment, R_2 is hydrogen and R_3 is lower alkyl or ZY;

25 Z is O, NR_4 or PR_4 ; Y is hydrogen or lower alkyl; ZY is $NR_4NR_5R_7$, NR_4OR_5 , ONR_4R_7 , NR_4C-R_5 or NR_4C-OR_5 .



30 In another especially preferred embodiment, $n=1$, R_2 is hydrogen and R_3 is lower alkyl which may be substituted or unsubstituted with an electron donating or electron withdrawing group, NR_4OR_5 , or ONR_4R_7 ,

In yet another especially preferred embodiment, $n = 1$, R_2 is hydrogen and

- 21 -

R_3 is lower alkyl which is unsubstituted or substituted with hydroxy or loweralkoxy, NR_4OR_5 or ONR_4R_7 , wherein R_4 , R_5 and R_7 are independently hydrogen or lower alkyl, R is aryl lower alkyl, which aryl group may be unsubstituted or substituted with an electron withdrawing group and R_1 is lower alkyl. In this embodiment it is most preferred that aryl is phenyl, which is unsubstituted or substituted with halo.

It is preferred that R_2 is hydrogen and R_3 is hydrogen, an alkyl group which is unsubstituted or substituted by at least an electron donating or electron withdrawing group or ZY . In this preferred embodiment, it is more preferred that R_3 is hydrogen, an alkyl group such as methyl, which is unsubstituted or substituted by an electron donating group, or NR_4OR_5 or ONR_4R_7 , wherein R_4 , R_5 and R_7 are independently hydrogen or lower alkyl. It is preferred that the electron donating group is lower alkoxy, and especially methoxy or ethoxy.

It is preferred that R_2 and R_3 are independently hydrogen, lower alkyl, or ZY ;
 Z is O, NR_4 or PR_4 ;
 Y is hydrogen or lower alkyl or

ZY is $NR_4R_5R_7$, NR_4OR_5 , ONR_4R_7 , $NR_4C(=O)R_5$ or $NR_4C(=O)OR_5$.


It is also preferred that R is aryl lower alkyl. The most preferred aryl for R is phenyl. The most preferred R group is benzyl. In a preferred embodiment, the aryl group may be unsubstituted or substituted with an electron donating or electron withdrawing group. If the aryl ring in R is substituted, it is most preferred that it is substituted with an electron withdrawing group, especially on the aryl ring. The most preferred electron withdrawing group for R is halo, especially fluoro.

The preferred R_1 is lower alkyl, especially methyl.

It is more preferred that R is aryl lower alkyl and R_1 is lower alkyl.

Further preferred compounds are compounds of Formula (Ib) wherein n is 1; R₂ is hydrogen; R₃ is hydrogen, a lower alkyl group, especially methyl which is substituted by an electron donating or electron withdrawing group or ZY; R is aryl, aryl lower alkyl, such as benzyl, wherein the aryl group is unsubstituted or substituted with an electron donating or electron withdrawing group and R₁ is lower alkyl. In this embodiment, it is more preferred that R₃ is hydrogen, a lower alkyl group, especially methyl, which may be substituted by electron donating group, such as lower alkoxy, (e.g., methoxy, ethoxy and the like), NR₄OR₅ or ONR₄R₇ wherein these groups are defined hereinabove.

The most preferred compounds utilized are those of the Formula (IIb):



Formula (IIb)

wherein

Ar is aryl, especially phenyl, which is unsubstituted or substituted with at least one electron donating group or electron withdrawing group, especially halo,

R₁ is lower alkyl, especially containing 1-3 carbon atoms; and

R₃ is as defined herein, but especially hydrogen, loweralkyl, which is unsubstituted or substituted by at least an electron donating group or electron withdrawing group or ZY. It is even more preferred that R₃ is, in this embodiment, hydrogen, an alkyl group which is unsubstituted or substituted by an electron donating group, NR₄OR₅ or ONR₄R₇. It is most preferred that R₃ is CH₂-Q, wherein Q is lower alkoxy, especially containing 1-3 carbon

- 23 -

atoms; NR_4OR_5 or ONR_4R_7 wherein R_4 is hydrogen or alkyl containing 1-3 carbon atoms, R_5 is hydrogen or alkyl containing 1-3 carbon atoms, and R_7 is hydrogen or alkyl containing 1-3 carbon atoms.

- 5 The most preferred R_1 is CH_3 . The most preferred R_3 is $\text{CH}_2\text{-Q}$, wherein Q is methoxy.

The most preferred aryl is phenyl. The most preferred halo is fluoro.


- 10 The most preferred compounds include:
(R)-2-acetamido-N-benzyl-3-methoxy-propionamide,
O-methyl-N-acetyl-D-serine-m-fluorobenzyl-amide;
O-methyl-N-acetyl-D-serine-p-fluorobenzyl-amide;
N-acetyl-D-phenylglycine benzylamide;
15 D-1,2-(N,O-dimethylhydroxylamino)-2-acetamide acetic acid benzylamide;
D-1,2-(O-methylhydroxylamino)-2-acetamido acetic acid benzylamide.

- It is to be understood that the various combinations and permutations of the Markush groups of R_1 , R_2 , R_3 , R and n described herein are contemplated to
20 be within the scope of the present invention. Moreover, the present invention also encompasses compounds and compositions which contain one or more elements of each of the Markush groupings in R_1 , R_2 , R_3 , n and R and the various combinations thereof. Thus, for example, the present invention contemplates that R_1 may be one or more of the substituents listed
25 hereinabove in combination with any and all of the substituents of R_2 , R_3 , and R with respect to each value of n.

- The compounds utilized in the present invention may contain one or more asymmetric carbons and may exist in racemic and optically active forms.
30 The configuration around each asymmetric carbon can be either the D or L form. It is well known in the art that the configuration around a chiral carbon atoms can also be described as R or S in the Cahn-Prelog-Ingold nomenclature system. All of the various configurations around each

asymmetric carbon, including the various enantiomers and diastereomers as well as racemic mixtures and mixtures of enantiomers, diastereomers or both are contemplated by the present invention.

- 5 In the principal chain, there exists asymmetry at the carbon atom to which the groups R_2 and R_3 are attached. When n is 1, the compounds of the present invention is of the formula



- 15 wherein R , R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R'_6 , R_7 , R_8 , R_{50} , Z and Y are as defined previously.

As used herein, the term configuration shall refer to the configuration around the carbon atom to which R_2 and R_3 are attached, even though other chiral
 20 centers may be present in the molecule. Therefore, when referring to a particular configuration, such as D or L, it is to be understood to mean the D or L stereoisomer at the carbon atom to which R_2 and R_3 are attached. However, it also includes all possible enantiomers and diastereomers at other chiral centers, if any, present in the compound.

25 The compounds of the present invention are directed to all the optical isomers, i.e., the compounds of the present invention are either the L-stereoisomer or the D-stereoisomer (at the carbon atom to which R_2 and R_3 are attached). These stereoisomers may be found in mixtures of the L and D
 30 stereoisomer, e.g., racemic mixtures. The D stereoisomer is preferred.

More preferred is a compound of Formula (III) in the R configuration, preferably substantially enantiopure, wherein the substituent R is benzyl which is unsubstituted or substituted with at least one halo group, wherein
 35 R_3 is $\text{CH}_2\text{-Q}$, wherein Q is lower alkoxy containing 1-3 carbon atoms and

wherein R_1 is methyl. Preferably R is unsubstituted benzyl or benzyl substituted with at least one halo group which is a fluoro group.

Depending upon the substituents, the present compounds may form addition salts as well. All of these forms are contemplated to be within the scope of this invention including mixtures of the stereoisomeric forms.

The manufacture of the utilized compounds is described in U.S. Patent Nos. 5,378,729 and 5,773,475, the contents of both of which are incorporated by reference.

The compounds utilized in the present invention are useful as such as depicted in the Formulae (Ib) or/and (IIb) or can be employed in the form of salts in view of its basic nature by the presence of the free amino group. Thus, the compounds of Formulae (Ib) or/and (IIb) form salts with a wide variety of acids, inorganic and organic, including pharmaceutically acceptable acids. The salts with therapeutically acceptable acids are of course useful in the preparation of formulation where enhanced water solubility is most advantageous.

These pharmaceutically acceptable salts have also therapeutic efficacy. These salts include salts of inorganic acids such as hydrochloric, hydroiodic, hydrobromic, phosphoric, metaphosphoric, nitric acid and sulfuric acids as well as salts of organic acids, such as tartaric, acetic, citric, malic, benzoic, perchloric, glycolic, gluconic, succinic, aryl sulfonic, (e.g., p-toluene sulfonic acids, benzenesulfonic), phosphoric, malonic, and the like.

The present invention is further directed to a method for the prevention, alleviation or/and treatment of a disease or condition as described above in a mammal, including a human being, comprising administering at least one compound of Formulae (Ib) or/and (IIb).

It is preferred that the compound utilized in the present invention is used in

therapeutically effective amounts.

The physician will determine the dosage of the present therapeutic agents which will be most suitable and it will vary with the form of administration and the particular compound chosen, and furthermore, it will vary with the patient under treatment, the age of the patient, the type of malady being treated. He will generally wish to initiate treatment with small dosages substantially less than the optimum dose of the compound and increase the dosage by small increments until the optimum effect under the circumstances is reached. When the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally. The compounds are useful in the same manner as comparable therapeutic agents and the dosage level is of the same order of magnitude as is generally employed with these other therapeutic agents.

In a preferred embodiment, the compounds of the present invention are administered in amounts ranging from about 1 mg to about 100 mg per kilogram of body weight per day. This dosage regimen may be adjusted by the physician to provide the optimum therapeutic response. Patients in need thereof may be treated with doses of the compound of the present invention of at least 100 mg/day, preferably of at least 200 mg/day, more preferably of at least 300 mg/day and most preferably of at least 400 mg/day. At the maximum, a patient in need thereof may be treated with doses at a maximum of 6 g/day, preferably a maximum of 3 g/day, more preferably a maximum of 1 g/day and most preferably a maximum of 400 mg/day.

In another preferred embodiment, the daily doses are increased until a predetermined daily dose is reached which is maintained during the further treatment.

In yet another preferred embodiment, several divided doses may be administered daily. For example, three doses per day may be administered,

- 27 -

preferably two doses per day. It is more preferred to administer a single dose per day.

5 In yet another preferred embodiment, an amount of the compounds of the present invention may be administered which results in a plasma concentration of 7 to 8 µg/ml (trough) and 9 to 12 µg/ml (peak), calculated as an average over a plurality of treated subjects.

10 A patient in need thereof may be treated with the compounds of the present invention for at least 1 week, preferably at least 2 weeks, more preferably at least 4 weeks, most preferably at least 8 weeks. The dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

15 The compounds of Formulae (Ib) or/and (IIb) may be administered in a convenient manner, such as by oral, intravenous (where water soluble), intramuscular, intrathecal or subcutaneous routes. Oral or/and i.v. administration is preferred.

20 The pharmaceutical composition of the present invention may be prepared for the treatment regimen as described above, in particular for the treatment with doses as described above, to effect plasma concentrations as described above, for administration periods or/and administration routes as specified in the embodiments of the present invention as described above.

25 In another preferred embodiment, the method of the present invention as described above for the treatment of a mammal, including a human being, in need thereof comprises administering a compound of the present invention in combination with administering a further active agent for the prevention, alleviation or/and treatment of CSD-associated conditions, or/and headache
30 such as migraine. The compound of the present invention and the further active agent for the prevention, alleviation or/and treatment of CSD-associated disorders or/and headache may be administered together, i.e. in

a single dose form, or may be administered separately, i.e. in a separate dose form. Thus, the pharmaceutical composition of the present invention may comprise a compound of the present invention as defined above and may additionally comprise a further agent for the prevention, alleviation or/and treatment of CSD-associated disorders or/and headache. The pharmaceutical composition may comprise a single dose form or may comprise a separate dose form comprising a first composition comprising a compound of the present invention as defined above and a second composition for the further agent.

10

The compounds of the present invention may be used for the preparation of a pharmaceutical composition as described above.

The compounds of Formulae (Ib) or/and (IIb) may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly into the food of the diet. For oral therapeutic administration, the active compound of Formulae (Ib) or/and (IIb) may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1 % of active compound of Formulae (Ib) or/and (IIb). The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80 % of the weight of the unit. The amount of active compound of Formulae (Ib) or/and (IIb) in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention contains between about 10 mg and 6 g active compound of Formulae (Ib) or/and (IIb).

30

The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn

starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it
5 may contain, in addition to materials of the above type, a liquid carrier.

Various other materials may be present as coatings or otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the
10 active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated
15 into sustained-release preparations and formulations. For example, sustained release dosage forms are contemplated wherein the active ingredient is bound to an ion exchange resin which, optionally, can be coated with a diffusion barrier coating to modify the release properties of the resin.

20 The active compound may also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to
25 prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In
30 all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or

- 30 -

dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying the freeze-drying technique plus any additional desired ingredient from previously sterile-filtered solution thereof.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agent, isotonic and absorption delaying agents for pharmaceutical active substances as well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions in dosage

unit form or ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

5 The specifics for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such as active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.

10

The principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore described. A unit dosage form can, for example, contain the principal active compound in amounts ranging from about 10 mg to about 6 g. Expressed in proportions, the active compound is generally present in from about 1 to about 750 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

15

20

As used herein the term "patient" or "subject" refers to a warm blooded animal, and preferably mammals, such as, for example, cats, dogs, horses, cows, pigs, mice, rats and primates, including humans. The preferred patient is a human.

25

The term "treat" refers to either relieving the pain associated with a disease or condition or alleviating the patient's disease or condition.

30

The compounds of the present invention are administered to a patient suffering from the aforementioned type of disorder in an analgesic effective amount. These amounts are equivalent to the therapeutically effective

amounts described hereinabove.

The following example shows the properties of SPM927 in reducing pain in a clinical trial in animals with CSD.

5

The used substance was SPM 927 which is the synonym for Harkoseride. The standard chemical nomenclature is (R)-2-acetamide-N-benzyl-3-methoxypropionamide.

10

Example

15

This study aims to demonstrate that pre-treatment with SPM 927 (3 doses) affects electrophysiological and biochemical events in a rat model of migraine (Cortical Spreading Depression, CSD). It was shown that SPM 927 treatment reduces the number of CSD-induced direct current (DC) – potentials and Calcitonin gene-related peptide (CGRP) levels in blood.

Materials and Methods

20

All animal experiments were carried out according to the National Institute of Health (NIH) guidelines for the care and use of laboratory animals, and approved by the Ethical Committee of the National Laboratory Animal Center, Kuopio, Finland. Altogether 77 adult male Wistar rats, purchased from Harlan, Netherlands, and weighing 250-350 g were used for the experiment. Animals were housed at a standard temperature (22 ± 1 °C) and in a light-controlled environment (lights on from 7 am to 9 pm) with *ad libitum* access to food and water. Animals were grouped as follows:

25

30

- 15 rats treated with SPM 927 (3 mg/kg; i.p.) 30 min before the CSD episode
- 15 rats treated with SPM 927 (10 mg/kg; i.p.) 30 min before the CSD episode
- 15 rats treated with SPM 927 (30 mg/kg; i.p.) 30 min before the CSD

episode

- 15 rats treated with Valproic acid (250 mg/kg; i.p.) 30 min before before the CSD episode
- 15 rats treated with Vehicle (2 ml/kg; i.p.) 30 min before CSD episode
- 5 • 2 sham rats without CSD episode (topical NaCl application) and without any treatment

Subgroups:

- 10 • 10 rats to DC-potential, CBF, and blood pH, pO₂, pCO₂, glucose and mean arterial pressure analysis (rats killed at 30 min after CSD, brains fresh-frozen)
- 5 rats to jugular vein cannulation (CGRP sampling) and dural as well as cortical CGRP immunocytochemistry (rats killed at 15 min after CSD)

15

Rats were anaesthetized with Equithesin (3 ml/kg) and placed in a stereotactic frame. The rectal temperature was maintained at 37.0 ± 1.0 °C with a homeothermic blanket system. A polyethylene catheter was inserted into the femoral artery in order to monitor arterial blood pressure and take blood samples for arterial pH, pO₂, pCO₂ and glucose. The arterial blood gases were measured with i-STAT portable clinical analyzer (I-STAT), arterial blood pressure monitored with Cardiacap II blood pressure analyzer (datex-Ohmeda, Helsinki, Finland) and blood glucose with standard glucose meter (Arkray, Japan). The measurements were taken 10 min before as well as 5 min after the CSD episode. The skin was opened by a medical incision and retracted laterally. Three skull burr holes were drilled in a row unilaterally. One was placed over the frontal cortex, the second frontoparietally and the third one parietally (Fig. 1). A laser-Doppler flow probe (Oxyflow, Oxford Optronics, UK) to monitor CBF and a non-invasive tungsten electrode for measuring direct current (DC) potential shifts were placed in the frontal and frontoparietal burr holes on the intact dura, respectively. The laser-Doppler flow probe was positioned in an area free of large pial and dural vessels to minimize a large-vessel contribution to the

20

25

30

signal. For the DC-potential measurement, a reference electrode was fixed in the neck. CSDs were elicited unilaterally by placing a KCl-soaked (3.0 M) piece of filter paper on the parietal opening for 5 min. The KCl exposure was terminated by flushing the opening with saline and placing a dry piece of filter paper on the opening. The CBF and DC-potentials were monitored continuously starting from 5 minutes before CSD and continuing up to 30 min after the KCl exposure.

15 min (n=15) after cessation of the 60 min CSD episode, rats were deeply anesthetized with pentobarbital, transcardially perfused first with PBS and then with 4 % paraformaldehyde in PBS. After perfusion the supratentorial dura (in toto) and coronal brain blocks were dissected and coronal brain blocks postfixed by immersion in the same fixative for 4 h. The cerebral dura was used as a whole-mount preparation and was subjected to CGRP immunostaining. For the coronal brain specimens, 12 μ m thick cryosections on glass slides or 40 μ m thick floating sections were cut with a cryostat from the blocks that have been cryoprotected with 20% sucrose for 48 h and frozen in liquid nitrogen-cooled isopentane. Briefly, after PBS washes and blocking serum incubation, the sections were reacted with primary antibody for 48 h at 4°C (rabbit anti-CGRP, Sigma RBI). The rinsed sections were incubated with biotinylated secondary antibody for 2 h (goat anti-rabbit, Vector Labs, CA) then with avidin-biotin complex for 2 h (ABC Elite Kit, Vector Labs), and the peroxidase containing avidin-biotin complex was visualized with 0.05 % Ni-diaminobenzidine (Ni-DAB) and 0.02 % H₂O₂. Finally, the sections were rinsed, air-dried, coverslipped and examined with a Leica 3000RB microscope. The density of immunoreactivity was determined from 3-4 sections in each animal (3-4 different microscopic fields from dura mater).

Following anesthesia (before CSD), a catheter was placed into the right jugular vein. 0.250 ml of blood was taken through the catheter for baseline measurement. For time course experiments further samples were taken at 10-15 and 20-25 min following initiation of CSD. Samples were stored in

prepared Eppendorf tubes containing the protease inhibitors aprotinin (1000 KU, Bayer, Germany) and Pefabloc™ (1 mg/ml, Boehringer Mannheim, Germany), immediately cold centrifuged and stored at -80 °C. The samples were acidified with trifluoroacetic acid and centrifuged at 6000 g for 20 min. The supernatant was extracted with Sep-Pak C-18 cartridges (Millipore, Waters, UK). Eluates were concentrated (dried) and dissolved in EIA buffer. CGRP concentrations were detected using a commercial CGRP EIA kit (S-3006, Bachem Distribution GmbH) according to the manufacturer's instructions.

All values were calculated as mean \pm standard deviation (SD) and differences were considered to be statistically significant as the $P < 0.05$ level. Statistical analysis was performed using StatsDirect statistical software. Differences among means were analyzed by using one-way analysis of variance (ANOVA). Dunnet's post-hoc test was applied for multiple comparisons with a control group.

Results

It is shown that SPM 927:

- suppresses cortical spreading depression (Table 1)
- reduces CSD induced release of CGRP in blood over time (Table 2)

Table I SPM 927 suppresses cortical spreading depression, i.e. reduces the number of direct current (DC) potentials

Group	Number of DC
Saline (n = 10)	4.5 \pm 0.6
SPM 927 (3 mg/kg) (n = 10)	4.2 \pm 0.4
SPM 927 (10 mg/kg) (n = 10)	3.3 \pm 0.4
SPM 927 (30 mg/kg) (n = 10)	3.5 \pm 0.6
Valproic acid (250 mg/kg) (n = 10)	3.7 \pm 0.3

Table II SPM 927 reduces cortical spreading depression (CSD) induced CGRP release expressed as percent of baseline levels during the first 25 min after induction of CSD.

Group	Baseline	10-15 min	20-25 min
Saline (n = 5)	100 ± 0%	150 ± 30%	190 ± 24%
SPM 927 (3 mg/kg) (n = 5)	100 ± 0%	126 ± 45%	35 ± 7%
SPM 927 (10 mg/kg) (n = 5)	100 ± 0%	114 ± 27%	66 ± 31%
SPM 927 (30 mg/kg) (n = 5)	100 ± 0%	92 ± 53%	71 ± 12%
Valproic acid (250 mg/kg) (n = 5)	100 ± 0%	56 ± 8%	71 ± 15%

5

Conclusion

These results demonstrate that SPM 927 is useful for the treatment of acute migraine, for the prophylactic treatment of migraine and for the treatment of other forms of chronic headache or/and CSD-associated disorders.


10

Claims

1. Use of a compound having the Formula (Ib)

5

10



Formula (Ib)

15

wherein

20

R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl lower alkyl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl or lower cycloalkyl lower alkyl, and R is unsubstituted or is substituted with at least one electron withdrawing group or/and at least one electron donating group;

25

R₁ is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic lower alkyl, lower alkyl heterocyclic, heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, each unsubstituted or substituted with at least one electron donating group or/and at least one electron withdrawing group;


30

R₂ and R₃ are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, halo, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, or Z-Y wherein R₂ and R₃ may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group; and wherein heterocyclic in R₂ and R₃ is furyl, thienyl, pyrazolyl, pyrrolyl, methylpyrrolyl, imidazolyl, indolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, piperidyl, pyrrolinyl, piperazinyl, quinolyl,

triazolyl, tetrazolyl, isoquinolyl, benzofuryl, benzothienyl, morpholinyl, benzoxazolyl, tetrahydrofuryl, pyranyl, indazolyl, purinyl, indolyl, pyrazolindinyl, imidazolyl, imidazolindinyl, pyrrolidinyl, furazanyl, N-methylindolyl, methylfuryl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridyl, epoxy, aziridino, oxetanyl, azetidiny or, when N is present in the heterocyclic, an N-oxide thereof;

Z is O, S, S(O)_a, NR₄, NR₆' or PR₄ or a chemical bond;

Y is hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic and Y may be unsubstituted or substituted with at least one electron donating group or/and at least one an electron withdrawing group, wherein heterocyclic has the same meaning as in R₂ or R₃ and, provided that when Y is halo, Z is a chemical bond, or ZY taken together is NR₄NR₅R₇, NR₄OR₅, ONR₄R₇, OPR₄R₅, PR₄OR₅, SNR₄R₇, NR₄SR₇, SPR₄R₅, PR₄SR₇, NR₄PR₅R₆, PR₄NR₅R₇, or N⁺R₅R₆R₇,



R₆' is hydrogen, lower alkyl, lower alkenyl, or lower alkynyl which may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group;

R₄, R₅ and R₆ are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, or lower alkynyl, wherein R₄, R₅ and R₆ may independently be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group; and

R₇ is R₆ or COOR₈ or COR₈, which R₇ may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group;

R_8 is hydrogen or lower alkyl, or aryl lower alkyl, and the aryl or alkyl group may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group; and

5 n is 1-4; and

a is 1-3,

or of a pharmaceutically acceptable salt thereof,

10 for the preparation of a pharmaceutical composition useful for the prevention, alleviation or/and treatment of headache or/and painful conditions associated with or/and caused by cortical spreading depression (CSD).

15 2. Use according to claim 1, wherein wherein the headache is chronic headache.

3. Use according to claims 1 or 2, wherein the headache is migraine.

20 4. Use according to claim 3 for the manufacture of a medicament for the treatment of acute migraine.

5. Use according to any one of claims 1 to 4, wherein one of R_2 and R_3 is hydrogen.

6. Use according to any one of claims 1 to 5 wherein n is 1.

7. Use according to any one of claims 1 to 6 wherein at least one of R_2 and R_3 is hydrogen and n is 1.

8. Use according to any one of claims 1 to 7 wherein R is aryl lower alkyl and R_1 is lower alkyl.

9. Use according to any one of claims 1 to 8 wherein

R_2 and R_3 are independently hydrogen, lower alkyl, or ZY;

Z is O, NR_4 or PR_4 ;

Y is hydrogen or lower alkyl or

5 ZY is $NR_4NR_5R_7$, NR_4OR_5 , ONR_4R_7 , $NR_4C(=O)R_5$ or $NR_4C(=O)OR_5$.

10. Use according to claim 9 wherein R_2 is hydrogen and R_3 is lower
10 alkyl, or ZY;

Z is O, NR_4 or PR_4 ;

Y is hydrogen or lower alkyl;

15 ZY is $NR_4NR_5R_7$, NR_4OR_5 , ONR_4R_7 , $NR_4C(=O)R_5$ or $NR_4C(=O)OR_5$.

11. Use according to claim 9 wherein R_2 is hydrogen and R_3 is lower alkyl,
which may be substituted or unsubstituted with at least one electron
donating group or/and at least one electron withdrawing group,
20 NR_4OR_5 , or/and ONR_4R_7 .

12. Use according to claim 9 wherein R_3 is lower alkyl which is
unsubstituted or substituted with hydroxy or lower alkoxy, NR_4OR_5
or/and ONR_4R_7 , wherein R_4 , R_5 and R_7 are independently hydrogen or
25 lower alkyl, R is aryl lower alkyl, which aryl group may be unsubstituted
or substituted with at least one electron withdrawing group and R_1 is
lower alkyl.

13. Use according to claim 12 wherein aryl is phenyl and is unsubstituted
30 or substituted with halo.

14. Use according to any one of claims 1 to 13 wherein the compound is
(R)-2-acetamido-N-benzyl-3-methoxy-propionamide;

O-methyl-N-acetyl-D-serine-m-fluorobenzylamide;


35 O-methyl-N-acetyl-D-serine-p-fluorobenzylamide;

N-acetyl-D-phenylglycinebenzylamide;

D-1,2-(N, O-dimethylhydroxylamino)-2-acetamide acetic acid benzylamide;

D-1,2-(O-methylhydroxylamino)-2-acetamido acetic acid benzylamide.

15. Use of any one of claims 1 to 14 where in the compound has the Formula (IIb)



Formula (IIb)

wherein

Ar is phenyl which is unsubstituted or substituted with at least one halo group;

20

R₃ is CH₂-Q, wherein Q is lower alkoxy containing 1-3 carbon atoms and R₁ is lower alkyl containing 1-3 carbon atoms


or of a pharmaceutically acceptable salt thereof.

16. Use according to claim 15 wherein Ar is unsubstituted phenyl.

17. Use according to claims 15 or 16 wherein halo is fluoro.

- 30 18. Use according to any one of claims 15 to 17 wherein R₃ is CH₂-Q, wherein Q is alkoxy containing 1-3 carbon atoms and Ar is unsubstituted phenyl.

- 35 19. Use of any one of claims 1 to 18, wherein the compound is in the R configuration having the formula



wherein

10 R is benzyl which is unsubstituted or substituted with at least one halo group;

R₃ is CH₂-Q, wherein Q is lower alkoxy containing 1-3 carbon atoms and R₁ is methyl

15

or a pharmaceutically acceptable salt thereof.

20. Use according to claim 19 which is substantially enantiopure.

20 21. Use according to claims 19 or 20 wherein R is unsubstituted benzyl.

22. Use according to claims 19 to 21 wherein halo is fluoro.

25 23. Use according to claims 19 to 22 wherein R₃ is CH₂-Q, wherein Q is alkoxy containing 1-3 carbon atoms and R is unsubstituted benzyl.

24. Use according to any one of claims 1 to 4, wherein the compound of Formula (Ib) is (R)-2-Acetamido-N-benzyl-3-methoxypropionamide or a pharmaceutically acceptable salt thereof.

25. Use according to claim 24 wherein the compound is substantially enantiopure.

35 26. Use according to any one of the preceding claims, wherein the pharmaceutical composition is prepared for treatment with doses of the

compound of at least 100 mg/day, preferably of at least 200 mg/day, more preferably of at least 300 mg/day, most preferably of at least 400 mg/day.

- 5 27. Use according to any one of the preceding claims, wherein the pharmaceutical composition is prepared for treatment with doses of the compound of at a maximum 6 g/day, preferably of at a maximum 3 g/day, more preferably of at a maximum 1 g/day and most preferably of at a maximum 400 mg/day.
28. Use according to any one of the preceding claims, wherein the pharmaceutical composition is prepared for treatment with increasing daily doses until a predetermined daily dose is reached which is maintained during the further treatment.
29. Use according to any one of the preceding claims, wherein the pharmaceutical composition is prepared for treatment in three doses per day, preferably two doses per day, more preferably in a single dose per day.
30. Use according to any one of the preceding claims, wherein the pharmaceutical composition is prepared for an administration resulting in a plasma concentration of 7 to 8 µg/ml (trough) and 9 to 12 µg/ml (peak), calculated as an average over a plurality of treated subjects.
31. Use according to any one of the preceding claims, wherein the pharmaceutical composition is prepared for treatment for at least one week, preferably at least two weeks, more preferably at least four weeks, most preferably at least eight weeks.
32. Use according to any one of the preceding claims, wherein the pharmaceutical composition is prepared for oral administration.


- 44 -

33. Use according to any one of the preceding claims, wherein the pharmaceutical composition comprises a further active agent for the prevention, alleviation or/and treatment of headache or/and CSD-associated disorders.
34. Use according to claim 33 wherein the pharmaceutical composition comprises a single dose form or comprises a separate dose form comprising a first composition comprising a compound as defined in any of the claims 1 and 5 to 25 and a second composition for the prevention, alleviation or/and the treatment of headache or/and CSD-associated disorders.
35. Use according to any one of the preceding claims wherein the pharmaceutical composition is prepared for administration in mammals.
36. Use according to claim 35 wherein the pharmaceutical composition is prepared for administration in humans.
37. A pharmaceutical composition comprising
- (a) a compound as defined in any of the claims 1 and 5 to 25, and
- (b) a further active agent for the prevention, alleviation or/and treatment of headache or/and CSD-associated disorders.
38. The pharmaceutical composition according to claim 37 which is a single dose form or comprises a separate dose form comprising a first composition comprising a compound as defined in any of the claims 1 and 5 to 25 and a second composition for the prevention, alleviation or/and the treatment of headache or/and CSD-associated disorders.

1/1

Figure 1

The Experimental Setting (modified from Paxinos and Watson rat brain atlas)



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/004047

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/05 A61P25/06 A61K31/16 A61K31/165

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/15922 A (RESEARCH CORPORATION TECHNOLOGIES, INC) 28 February 2002 (2002-02-28) claims 1,15,20,34 page 1, line 10 - page 2, line 2 page 17, line 34 - page 18, line 7 page 27, line 19 - page 29, line 13 page 30, line 32 - page 31, line 6 page 50, line 25 - line 34 page 55, line 20 - line 26 page 56, line 24 - page 57, line 12	1-38
A	WO 02/074297 A (SCHWARZ PHARMA AG; SELVE, NORMA) 26 September 2002 (2002-09-26) cited in the application abstract ----- -/--	1-38



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the International search

9 June 2005

Date of mailing of the international search report

17/06/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Langer, O

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/004047

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/074784 A (SCHWARZ PHARMA AG; SELVE, NORMA) 26 September 2002 (2002-09-26) cited in the application abstract	1-38
A	US 5 773 475 A (KOHN ET AL) 30 June 1998 (1998-06-30) cited in the application the whole document	1-38
A	US 5 378 729 A (KOHN ET AL) 3 January 1995 (1995-01-03) cited in the application abstract	1-38

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/004047

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0215922	A	28-02-2002	AU 8676301 A	04-03-2002
			CA 2419285 A1	28-02-2002
			EP 1365787 A2	03-12-2003
			EP 1486205 A1	15-12-2004
			EP 1486206 A1	15-12-2004
			JP 2004506692 T	04-03-2004
			WO 0215922 A2	28-02-2002
			US 2004097416 A1	20-05-2004
			US 2004087508 A1	06-05-2004
			US 2002086828 A1	04-07-2002
WO 02074297	A	26-09-2002	EP 1243263 A1	25-09-2002
			AT 228358 T	15-12-2002
			BR 0208141 A	02-03-2004
			CA 2430470 A1	26-09-2002
			CN 1498104 A	19-05-2004
			DE 60100055 D1	09-01-2003
			DE 60100055 T2	24-07-2003
			DK 1243263 T3	17-03-2003
			WO 02074297 A1	26-09-2002
			EP 1383487 A1	28-01-2004
			ES 2185606 T3	01-05-2003
			HK 1048763 A1	01-08-2003
			HU 0303983 A2	28-04-2004
			JP 2004524337 T	12-08-2004
			MX PA03006438 A	24-05-2004
			NO 20033918 A	04-09-2003
			PT 1243263 T	31-03-2003
			SI 21169 A	31-10-2003
			SK 12902003 A3	08-06-2004
			US 2004220077 A1	04-11-2004
			ZA 200303319 A	08-07-2003
WO 02074784	A	26-09-2002	EP 1243262 A1	25-09-2002
			AU 2002257681 A2	03-10-2002
			BR 0205823 A	21-10-2003
			CA 2419397 A1	26-09-2002
			CN 1498103 A	19-05-2004
			CZ 20032763 A3	14-01-2004
			WO 02074784 A2	26-09-2002
			EP 1373300 A2	02-01-2004
			HU 0303600 A2	01-03-2004
			JP 2004524340 T	12-08-2004
			MX PA03008467 A	08-12-2003
			NO 20033629 A	15-08-2003
			NZ 523865 A	24-12-2004
			PL 362985 A1	15-11-2004
			SI 21170 A	31-10-2003
			SK 12832003 A3	03-02-2004
			US 2003171300 A1	11-09-2003
			US 2005085423 A1	21-04-2005
			ZA 200300858 A	09-07-2003
US 5773475	A	30-06-1998	US RE38551 E1	06-07-2004
			US 6048899 A	11-04-2000
US 5378729	A	03-01-1995	AT 161824 T	15-01-1998
			AU 657985 B2	30-03-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/004047

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5378729	A	AU 2162192 A	08-01-1993
		CA 2110693 A1	10-12-1992
		DE 69223965 D1	12-02-1998
		DE 69223965 T2	30-04-1998
		EP 0592490 A1	20-04-1994
		JP 6510985 T	08-12-1994
		JP 3330374 B2	30-09-2002
		JP 2002241355 A	28-08-2002
		US 5654301 A	05-08-1997
		WO 9221648 A1	10-12-1992
		AT 214384 T	15-03-2002
		AU 641160 B2	16-09-1993
		AU 5519590 A	28-02-1991
		CA 2017217 A1	19-11-1990
		DE 69033931 D1	18-04-2002
		DE 69033931 T2	28-11-2002
		DK 400440 T3	01-07-2002
		EP 0400440 A1	05-12-1990
		ES 2171389 T3	16-09-2002
		JP 3506045 T	26-12-1991
		NZ 233728 A	28-04-1993
		PT 94103 A ,B	08-01-1991
		WO 9015069 A2	13-12-1990
		AT 92315 T	15-08-1993
		CA 1340904 C	22-02-2000
		DE 3786865 D1	09-09-1993
		DE 3786865 T2	09-12-1993
		DK 526087 A	08-04-1988
		EP 0263506 A2	13-04-1988
		ES 2005042 A6	16-02-1989
		ES 2058085 T3	01-11-1994
		GR 871549 A1	12-02-1988
		IE 61437 B1	02-11-1994
		JP 2580196 B2	12-02-1997
		JP 63132832 A	04-06-1988
		NZ 222045 A	27-10-1989
		PT 85869 A ,B	01-11-1987
		AT 62222 T	15-04-1991
		AU 596573 B2	10-05-1990
		AU 5371186 A	21-08-1986
		CA 1340902 C	22-02-2000
		DE 3678469 D1	08-05-1991
		DK 72686 A	16-08-1986
		EP 0194464 A1	17-09-1986
		ES 8708142 A1	01-12-1987
		GR 860455 A1	18-06-1986
		IE 58422 B1	22-09-1993
		JP 1972065 C	27-09-1995